Dr. Bruce D. Forrest has been appointed chief development officer at Omni Bio Pharmaceutical, Inc. Dr. Forrest currently serves as president of B D Forrest & Co., Inc., a pharma/biopharma consulting firm that provides scientific strategy and business development support, and has worked with Omni Bio during the past year. 
 
In his expanded role, he will oversee the development plan for Omni Bio’s lead Fc fusion recombinant AAT molecule for the potential treatment of type 1 diabetes, graft versus host disease and various inflammatory conditions. He will also provide leadership for the cell line optimization and product manufacturing partnership with Gallus BioPharmaceuticals, Inc. 
 
Dr. Forrest has more than 25 years of industry experience in pharmaceutical development, including vaccines and biopharmaceuticals. Dr. Forrest was previously senior vice president in Vaccines R&D at Wyeth Pharmaceuticals, where he was responsible for clinical and development activities for all late phase programs. He also served as head of Wyeth’s R&D organization in Japan and held various clinical research roles at Chiron Corp. and United Biomedical, Inc. 
 
Dr. Bruce E. Schneider, chief executive officer of Omni Bio, said, “We are extremely pleased to have Dr. Forrest serve in this role for Omni Bio. His background as an immunologist and his proven track record in managing both non-clinical and clinical R&D functions will be enormously helpful to us as we pursue the ongoing development of recombinant AAT.”